Ovarian Cancer from Anatomy to Functional Imaging

详细信息    查看全文

• 作者：Stephanie Nougaret ; Hebert Alberto Vargas ; Mariana Horta…
• 关键词：Ovarian carcinoma ; Gynecologic malignancy ; Hematologic malignancy ; Urogenital imaging
• 刊名：Current Radiology Reports
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：3
• 期：11
• 全文大小：1,420 KB
• 参考文献：Papers of particular interest, published recently, have been highlighted as: 鈥?Of importance 鈥⑩€?Of major importance1.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5鈥?9.CrossRef PubMed
  2.Russell SE, McCluggage WG. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol. 2004;203(2):617鈥?.CrossRef PubMed
  3.鈥⑩€?Vargas HA, Micco M, Hong SI, Goldman DA, Dao F, Weigelt B, et al. Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study. Radiology. 2015;274(3):742鈥?1. First study exploring the relationships between CT imaging traits and CLOVAR (classification of ovarian cancer) gene signatures in HGSOC.
  4.Fleischer AC, Rodgers WH, Kepple DM, Williams LL, Jones HW 3rd, Gross PR. Color Doppler sonography of benign and malignant ovarian masses. Radiographics. 1992;12(5):879鈥?5.CrossRef PubMed
  5.Brown DL, Frates MC, Laing FC, DiSalvo DN, Doubilet PM, Benson CB, et al. Ovarian masses: can benign and malignant lesions be differentiated with color and pulsed Doppler US? Radiology. 1994;190(2):333鈥?.CrossRef PubMed
  6.Brown DL, Doubilet PM, Miller FH, Frates MC, Laing FC, DiSalvo DN, et al. Benign and malignant ovarian masses: selection of the most discriminating gray-scale and Doppler sonographic features. Radiology. 1998;208(1):103鈥?0.CrossRef PubMed
  7.鈥⑩€?Levine D, Brown DL, Andreotti RF, Benacerraf B, Benson CB, Brewster WR, et al. Management of asymptomatic ovarian and other adnexal cysts imaged at US: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology. 2010;256(3):943鈥?4. Consensus article detailing ultrasound imaging criteria to distinguish malignant versus benign ovarian tumor on Ultrasound.
  8.Timmerman D, Ameye L, Fischerova D, Epstein E, Melis GB, Guerriero S, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ. 2010;341:c6839.PubMed Central CrossRef PubMed
  9.Kaijser J, Van Gorp T, Van Hoorde K, Van Holsbeke C, Sayasneh A, Vergote I, et al. A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass. Gynecol Oncol. 2013;129(2):377鈥?3.CrossRef PubMed
  10.Timmerman D, Testa AC, Bourne T, Ferrazzi E, Ameye L, Konstantinovic ML, et al. Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. J Clin. 2005;23(34):8794鈥?01.CrossRef
  11.Timmerman D, Van Calster B, Testa AC, Guerriero S, Fischerova D, Lissoni AA, et al. Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA group. Ultrasound Obstet Gynecol. 2010;36(2):226鈥?4.CrossRef PubMed
  12.Meys EM, Rutten IJ, Kruitwagen RF, Slangen BF, Bergmans MG, Mertens HJ, et al. Investigating the performance and cost-effectiveness of the simple ultrasound-based rules compared to the risk of malignancy index in the diagnosis of ovarian cancer (SUBSONiC-study): protocol of a prospective multicenter cohort study in the Netherlands. BMC Cancer. 2015;15:482.PubMed Central CrossRef PubMed
  13.Van Gorp T, Veldman J, Van Calster B, Cadron I, Leunen K, Amant F, et al. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. Eur J Cancer. 2012;48(11):1649鈥?6.CrossRef PubMed
  14.Sohaib SA, Mills TD, Sahdev A, Webb JA, Vantrappen PO, Jacobs IJ, et al. The role of magnetic resonance imaging and ultrasound in patients with adnexal masses. Clin Radiol. 2005;60(3):340鈥?.CrossRef PubMed
  15.Hricak H, Chen M, Coakley FV, Kinkel K, Yu KK, Sica G, et al. Complex adnexal masses: detection and characterization with MR imaging鈥攎ultivariate analysis. Radiology. 2000;214(1):39鈥?6.CrossRef PubMed
  16.Kinkel K, Lu Y, Mehdizade A, Pelte MF, Hricak H. Indeterminate ovarian mass at US: incremental value of second imaging test for characterization鈥攎eta-analysis and Bayesian analysis. Radiology. 2005;236(1):85鈥?4.CrossRef PubMed
  17.Bernardin L, Dilks P, Liyanage S, Miquel ME, Sahdev A, Rockall A. Effectiveness of semi-quantitative multiphase dynamic contrast-enhanced MRI as a predictor of malignancy in complex adnexal masses: radiological and pathological correlation. Eur Radiol. 2012;22(4):880鈥?0.CrossRef PubMed
  18.Li X, Hu JL, Zhu LM, Sun XH, Sheng HQ, Zhai N, et al. The clinical value of dynamic contrast-enhanced MRI in differential diagnosis of malignant and benign ovarian lesions. Tumour Biol. 2015;36:5515鈥?2.CrossRef PubMed
  19.Tang YZ, Benardin L, Booth TC, Miquel ME, Dilks P, Sahdev A, et al. Use of an internal reference in semi-quantitative dynamic contrast-enhanced MRI (DCE MRI) of indeterminate adnexal masses. Br J Radiol. 1043;2014(87):20130730.
  20.Thomassin-Naggara I, Bazot M, Darai E, Callard P, Thomassin J, Cuenod CA. Epithelial ovarian tumors: value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis. Radiology. 2008;248(1):148鈥?9.CrossRef PubMed
  21.Thomassin-Naggara I, Darai E, Cuenod CA, Rouzier R, Callard P, Bazot M. Dynamic contrast-enhanced magnetic resonance imaging: a useful tool for characterizing ovarian epithelial tumors. J Magn Reson Imaging. 2008;28(1):111鈥?0.CrossRef PubMed
  22.Sohaib SA, Sahdev A, Van Trappen P, Jacobs IJ, Reznek RH. Characterization of adnexal mass lesions on MR imaging. AJR Am J Roentgenol. 2003;180(5):1297鈥?04.CrossRef PubMed
  23.Rockall AG. Diffusion weighted MRI in ovarian cancer. Curr Opin Oncol. 2014;26(5):529鈥?5.CrossRef PubMed
  24.Li W, Chu C, Cui Y, Zhang P, Zhu M. Diffusion-weighted MRI: a useful technique to discriminate benign versus malignant ovarian surface epithelial tumors with solid and cystic components. Abdom Imaging. 2012;37(5):897鈥?03.CrossRef PubMed
  25.Takeuchi M, Matsuzaki K, Nishitani H. Diffusion-weighted magnetic resonance imaging of ovarian tumors: differentiation of benign and malignant solid components of ovarian masses. J Comput Assist Tomogr. 2010;34(2):173鈥?.CrossRef PubMed
  26.Fujii S, Kakite S, Nishihara K, Kanasaki Y, Harada T, Kigawa J, et al. Diagnostic accuracy of diffusion-weighted imaging in differentiating benign from malignant ovarian lesions. J Magn Reson Imaging. 2008;28(5):1149鈥?6.CrossRef PubMed
  27.Balaban M, Idilman IS, Toprak H, Unal O, Ipek A, Kocakoc E. The utility of diffusion-weighted magnetic resonance imaging in differentiation of endometriomas from hemorrhagic ovarian cysts. Clin Imaging. 2015;39:830鈥?.CrossRef PubMed
  28.Nakayama T, Yoshimitsu K, Irie H, Aibe H, Tajima T, Nishie A, et al. Diffusion-weighted echo-planar MR imaging and ADC mapping in the differential diagnosis of ovarian cystic masses: usefulness of detecting keratinoid substances in mature cystic teratomas. J Magn Reson Imaging. 2005;22(2):271鈥?.CrossRef PubMed
  29.Zhang H, Zhang GF, Wang TP, Zhang H. Value of 3.0 T diffusion-weighted imaging in discriminating thecoma and fibrothecoma from other adnexal solid masses. J Ovarian Res. 2013;6(1):58.PubMed Central CrossRef PubMed
  30.Nougaret S, Tirumani SH, Addley H, Pandey H, Sala E, Reinhold C. Pearls and pitfalls in MRI of gynecologic malignancy with diffusion-weighted technique. AJR Am J Roentgenol. 2013;200(2):261鈥?6.CrossRef PubMed
  31.Thomassin-Naggara I, Darai E, Cuenod CA, Fournier L, Toussaint I, Marsault C, et al. Contribution of diffusion-weighted MR imaging for predicting benignity of complex adnexal masses. Eur Radiol. 2009;19(6):1544鈥?2.CrossRef PubMed
  32.Oh JW, Rha SE, Oh SN, Park MY, Byun JY, Lee A. Diffusion-weighted MRI of epithelial ovarian cancers: correlation of apparent diffusion coefficient values with histologic grade and surgical stage. Eur J Radiol. 2015;84(4):590鈥?.CrossRef PubMed
  33.鈥?Thomassin-Naggara I, Toussaint I, Perrot N, Rouzier R, Cuenod CA, Bazot M, et al. Characterization of complex adnexal masses: value of adding perfusion- and diffusion-weighted MR imaging to conventional MR imaging. Radiology. 2011;258(3):793鈥?03. First article demonstrating the added value of combining conventional imaging, DWI and DCE to characterize ovarian tumor.
  34.鈥?Nougaret S, Addley HC, Colombo PE, Fujii S, Al Sharif SS, Tirumani SH, et al. Ovarian carcinomatosis: how the radiologist can help plan the surgical approach. Radiographics. 2012;32(6):1775鈥?00 (discussion 800鈥?). Article detailing the different aspect of peritoneal spread and resection criteria.
  35.Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012;124(1):10鈥?.CrossRef PubMed
  36.Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol. 2014;134(3):455鈥?1.PubMed Central CrossRef PubMed
  37.Vargas HA, Burger IA, Goldman DA, Micco M, Sosa RE, Weber W, et al. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. Eur Radiol. 2015. doi:10.鈥?007/鈥媠00330-015-3729-9 .
  38.Qayyum A, Coakley FV, Westphalen AC, Hricak H, Okuno WT, Powell B. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol. 2005;96(2):301鈥?.CrossRef PubMed
  39.Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ. Staging of advanced ovarian cancer: comparison of imaging modalities鈥攔eport from the Radiological Diagnostic Oncology Group. Radiology. 2000;215(3):761鈥?.CrossRef PubMed
  40.鈥⑩€?Forstner R, Sala E, Kinkel K, Spencer JA. ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol. 2010;20(12):2773鈥?0. European Guidelines regarding ovarian cancer management on imaging.
  41.Javitt MC. ACR appropriateness criteria on staging and follow-up of ovarian cancer. J Am Coll Radiol. 2007;4(9):586鈥?.CrossRef PubMed
  42.Forstner R, Hricak H, Occhipinti KA, Powell CB, Frankel SD, Stern JL. Ovarian cancer: staging with CT and MR imaging. Radiology. 1995;197(3):619鈥?6.CrossRef PubMed
  43.Coakley FV, Choi PH, Gougoutas CA, Pothuri B, Venkatraman E, Chi D, et al. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology. 2002;223(2):495鈥?.CrossRef PubMed
  44.Low RN, Barone RM, Lacey C, Sigeti JS, Alzate GD, Sebrechts CP. Peritoneal tumor: MR imaging with dilute oral barium and intravenous gadolinium-containing contrast agents compared with unenhanced MR imaging and CT. Radiology. 1997;204(2):513鈥?0.CrossRef PubMed
  45.Low RN, Semelka RC, Worawattanakul S, Alzate GD, Sigeti JS. Extrahepatic abdominal imaging in patients with malignancy: comparison of MR imaging and helical CT, with subsequent surgical correlation. Radiology. 1999;210(3):625鈥?2.CrossRef PubMed
  46.鈥?Fujii S, Matsusue E, Kanasaki Y, Kanamori Y, Nakanishi J, Sugihara S, et al. Detection of peritoneal dissemination in gynecological malignancy: evaluation by diffusion-weighted MR imaging. Eur Radiol. 2008;18(1):18鈥?3. First study demonstrating the added value of diffusion weighted imaging in peritoneal carcinomatosis.
  47.Low RN, Sebrechts CP, Barone RM, Muller W. Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings鈥攁 feasibility study. AJR Am J Roentgenol. 2009;193(2):461鈥?0.CrossRef PubMed
  48.Kyriazi S, Collins DJ, Morgan VA, Giles SL, deSouza NM. Diffusion-weighted imaging of peritoneal disease for noninvasive staging of advanced ovarian cancer. Radiographics. 2010;30(5):1269鈥?5.CrossRef PubMed
  49.鈥⑩€?Mitchell DG, Javitt MC, Glanc P, Bennett GL, Brown DL, Dubinsky T, et al. ACR appropriateness criteria staging and follow-up of ovarian cancer. J Am Coll Radiol. 2013;10(11):822鈥?. ACR guidelines for the management of ovarian cancer on imaging.
  50.Nam EJ, Yun MJ, Oh YT, Kim JW, Kim JH, Kim S, et al. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol. 2010;116(3):389鈥?4.CrossRef PubMed
  51.Hynninen J, Kemppainen J, Lavonius M, Virtanen J, Matomaki J, Oksa S, et al. A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer. Gynecol Oncol. 2013;131(2):389鈥?4.CrossRef PubMed
  52.Queiroz MA, Kubik-Huch RA, Hauser N, Freiwald-Chilla B, von Schulthess G, Froehlich JM, et al. PET/MRI and PET/CT in advanced gynaecological tumours: initial experience and comparison. Eur Radiol. 2015;25(8):2222鈥?0.CrossRef PubMed
  53.Fruscio R, Sina F, Dolci C, Signorelli M, Crivellaro C, Dell鈥橝nna T, et al. Preoperative 18F-FDG PET/CT in the management of advanced epithelial ovarian cancer. Gynecol Oncol. 2013;131(3):689鈥?3.CrossRef PubMed
  54.Dauwen H, Van Calster B, Deroose CM, Op de Beeck K, Amant F, Neven P, et al. PET/CT in the staging of patients with a pelvic mass suspicious for ovarian cancer. Gynecol Oncol. 2013;131(3):694鈥?00.CrossRef PubMed
  55.De Iaco P, Musto A, Orazi L, Zamagni C, Rosati M, Allegri V, et al. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy. Eur J Radiol. 2011;80(2):e98鈥?03.CrossRef PubMed
  56.Micco M, Sala E, Lakhman Y, Hricak H, Vargas HA. Role of imaging in the pretreatment evaluation of common gynecological cancers. Womens Health (Lond Engl). 2014;10(3):299鈥?21.CrossRef PubMed
  57.Michielsen K, Vergote I, Op de Beeck K, Amant F, Leunen K, Moerman P, et al. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. Eur Radiol. 2014;24(4):889鈥?01.CrossRef PubMed
  58.Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996;14(5):1545鈥?1.PubMed
  59.Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995;21(3):215鈥?5.CrossRef PubMed
  60.Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228鈥?7.CrossRef PubMed
  61.Ferrandina G, Ludovisi M, Corrado G, Carone V, Petrillo M, Scambia G. Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol. 2008;109(2):187鈥?3.CrossRef PubMed
  62.Kyriazi S, Collins DJ, Messiou C, Pennert K, Davidson RL, Giles SL, et al. Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging鈥攙alue of histogram analysis of apparent diffusion coefficients. Radiology. 2011;261(1):182鈥?2.CrossRef PubMed
  63.Addley HC, Vargas HA, Moyle PL, Crawford R, Sala E. Pelvic imaging following chemotherapy and radiation therapy for gynecologic malignancies. Radiographics. 2010;30(7):1843鈥?6.CrossRef PubMed
  64.鈥?Sala E, Kataoka MY, Priest AN, Gill AB, McLean MA, Joubert I, et al. Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects. Radiology. 2012;263(1):149鈥?59. Study demonstrating the heterogeneity of tumor response in primary tumor and implants after chemotherapy.
  65.Priest AN, Gill AB, Kataoka M, McLean MA, Joubert I, Graves MJ, et al. Dynamic contrast-enhanced MRI in ovarian cancer: initial experience at 3 tesla in primary and metastatic disease. Magn Reson Med. 2010;63(4):1044鈥?.CrossRef PubMed
  66.Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol. 2006;24(20):3282鈥?2.CrossRef PubMed
  67.Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol. 2005;23(30):7445鈥?3.CrossRef PubMed
  68.Rockall AG, Avril N, Lam R, Iannone R, Mozley PD, Parkinson C, et al. Repeatability of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent ovarian carcinoma: test-retest measurements for tumor FDG uptake, diameter, and volume. Clin Cancer Res. 2014;20(10):2751鈥?0.CrossRef PubMed
  69.Martoni AA, Fanti S, Zamagni C, Rosati M, De Iaco P, D鈥橢rrico Grigioni A, et al. [18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy. Q J Nucl Med Mol Imaging. 2011;55(1):81鈥?0.PubMed
  70.Forstner R, Hricak H, Powell CB, Azizi L, Frankel SB, Stern JL. Ovarian cancer recurrence: value of MR imaging. Radiology. 1995;196(3):715鈥?0.CrossRef PubMed
  71.Coakley FV, Hricak H. Imaging of peritoneal and mesenteric disease: key concepts for the clinical radiologist. Clin Radiol. 1999;54(9):563鈥?4.CrossRef PubMed
  72.Kurtz AB, Tsimikas JV, Tempany CM, Hamper UM, Arger PH, Bree RL, et al. Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis鈥攔eport of the Radiology Diagnostic Oncology Group. Radiology. 1999;212(1):19鈥?7.CrossRef PubMed
  73.Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2009;71(1):164鈥?4.CrossRef PubMed
  74.Hameeduddin A, Sahdev A. Diffusion-weighted imaging and dynamic contrast-enhanced MRI in assessing response and recurrent disease in gynaecological malignancies. Cancer Imaging. 2015;15:3.PubMed Central CrossRef PubMed
  75.Nair VS, Gevaert O, Davidzon G, Plevritis SK, West R. NF-kappaB protein expression associates with (18)F-FDG PET tumor uptake in non-small cell lung cancer: a radiogenomics validation study to understand tumor metabolism. Lung Cancer. 2014;83(2):189鈥?6.PubMed Central CrossRef PubMed
  76.Karlo CA, Di Paolo PL, Chaim J, Hakimi AA, Ostrovnaya I, Russo P, et al. Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology. 2014;270(2):464鈥?1.PubMed Central CrossRef PubMed
  77.Oh J, Sutton E, Veeraraghavan H, Apte A, Morris E, Deasy J. TU-AB-BRA-09: radiomics and radiogenomics for breast cancer using magnetic resonance imaging. Med Phys. 2015;42(6):3588.CrossRef
  
• 作者单位：Stephanie Nougaret (1) (2) (3) (4)
  Hebert Alberto Vargas (1)
  Mariana Horta (5)
  Yulia Lakhman (1)
  Evis Sala (1)
  
  1. Department of Radiology, Memorial Sloan Kettering Cancer Center, 300 E 66th St, Room 703, New York, NY, 10065, USA
  2. Department of Imaging, CHU Montpellier, St Eloi Hospital, Montpellier, France
  3. IRCM, Institut de Recherche en Canc茅rologie de Montpellier, Montpellier, F-34298, France
  4. INSERM, Unit 896, Montpellier, F-34298, France
  5. Department of Radiology, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal
  
• 刊物主题：Imaging / Radiology;
• 出版者：Springer US
• ISSN：2167-4825

文摘

Ovarian carcinoma is the most common cause of death from a gynecologic malignancy with more than 2/3 of patients having peritoneal involvement at the time of diagnosis. Treatment is principally dependent on stage and extent of disease and center expertise. Patients with advanced disease are treated either by primary cytoreductive surgery (debulking) followed by adjuvant chemotherapy, or neoadjuvant chemotherapy prior to debulking surgery. Imaging at the time of initial presentation has become critical in the selection of patients who may benefit from neoadjuvant chemotherapy instead of primary debulking surgery. Moreover, with the development of neoadjuvant treatment and molecularly targeted drug, evaluation of treatment response has becoming both critical and challenging. Indeed, evaluating early tumor changes, for example, relies more on functional (assessment of tumor vascularity, necrosis, etc.) rather than macroscopic changes in tumor size. This highlights a need for novel non-invasive biomarkers to allow implementation of personalized treatment. Thus, in this review, we focus on the advances of imaging in the diagnosis and management of ovarian cancer including functional imaging and radiogenomics. Keywords Ovarian carcinoma Gynecologic malignancy Hematologic malignancy Urogenital imaging